Research Analysts Set Expectations for BCYC FY2025 Earnings

Key Points

• Cantor Fitzgerald has raised its FY2025 earnings per share estimate for Bicycle Therapeutics to ($3.73), reflecting an increase from a previous estimate of ($3.87).
• Bicycle Therapeutics reported a quarterly earnings miss with an EPS of ($1.14), falling short of analysts' expectations of ($0.95) and generating $2.90 million in revenue against an anticipated $9.43 million.
• The current consensus rating for Bicycle Therapeutics' stock is a "Moderate Buy", with a target price averaging $22.22 from various analysts.

Bicycle Therapeutics PLC Sponsored ADR (NASDAQ:BCYC - Free Report) - Cantor Fitzgerald increased their FY2025 earnings per share estimates for Bicycle Therapeutics in a research report issued to clients and investors on Monday, August 11th. Cantor Fitzgerald analyst L. Watsek now anticipates that the company will post earnings of ($3.73) per share for the year, up from their previous estimate of ($3.87). The consensus estimate for Bicycle Therapeutics' current full-year earnings is ($3.06) per share. Cantor Fitzgerald also issued estimates for Bicycle Therapeutics' FY2026 earnings at ($3.59) EPS.

Bicycle Therapeutics (NASDAQ:BCYC - Get Free Report) last issued its quarterly earnings results on Friday, August 8th. The company reported ($1.14) EPS for the quarter, missing analysts' consensus estimates of ($0.95) by ($0.19). Bicycle Therapeutics had a negative net margin of 1,257.00% and a negative return on equity of 32.43%. The firm had revenue of $2.90 million for the quarter, compared to analysts' expectations of $9.43 million.

A number of other brokerages have also weighed in on BCYC. B. Riley lowered their price objective on shares of Bicycle Therapeutics from $17.00 to $14.00 and set a "neutral" rating for the company in a report on Friday, May 2nd. JMP Securities dropped their price objective on Bicycle Therapeutics from $22.00 to $10.00 and set a "market outperform" rating for the company in a report on Tuesday. Royal Bank Of Canada set a $27.00 target price on Bicycle Therapeutics and gave the company an "outperform" rating in a research note on Monday. Needham & Company LLC reiterated a "buy" rating and set a $29.00 price objective on shares of Bicycle Therapeutics in a research note on Friday, May 2nd. Finally, Oppenheimer reissued an "outperform" rating and issued a $44.00 target price (down previously from $48.00) on shares of Bicycle Therapeutics in a report on Monday. Three equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company's stock. Based on data from MarketBeat.com, Bicycle Therapeutics presently has a consensus rating of "Moderate Buy" and a consensus target price of $22.22.

Bicycle Therapeutics Stock Down 3.2%

Shares of NASDAQ BCYC opened at $7.22 on Wednesday. The firm has a market capitalization of $500.01 million, a P/E ratio of -2.06 and a beta of 1.44. The stock's 50-day simple moving average is $7.92 and its two-hundred day simple moving average is $8.92. Bicycle Therapeutics has a twelve month low of $6.10 and a twelve month high of $28.67.

Institutional Investors Weigh In On Bicycle Therapeutics

Several hedge funds have recently made changes to their positions in BCYC. Principal Financial Group Inc. raised its position in shares of Bicycle Therapeutics by 55.3% in the 1st quarter. Principal Financial Group Inc. now owns 631,260 shares of the company's stock worth $5,359,000 after acquiring an additional 224,790 shares in the last quarter. Baker BROS. Advisors LP lifted its stake in shares of Bicycle Therapeutics by 15.8% during the fourth quarter. Baker BROS. Advisors LP now owns 10,885,357 shares of the company's stock worth $152,395,000 after buying an additional 1,485,397 shares during the period. Exchange Traded Concepts LLC grew its holdings in shares of Bicycle Therapeutics by 90.3% during the first quarter. Exchange Traded Concepts LLC now owns 12,764 shares of the company's stock valued at $108,000 after buying an additional 6,057 shares during the last quarter. Fcpm Iii Services B.V. increased its position in shares of Bicycle Therapeutics by 47.5% in the 4th quarter. Fcpm Iii Services B.V. now owns 3,452,330 shares of the company's stock valued at $48,333,000 after acquiring an additional 1,112,369 shares during the period. Finally, Nan Fung Group Holdings Ltd raised its stake in Bicycle Therapeutics by 118.3% in the 4th quarter. Nan Fung Group Holdings Ltd now owns 68,943 shares of the company's stock worth $965,000 after acquiring an additional 37,358 shares during the last quarter. 86.15% of the stock is currently owned by hedge funds and other institutional investors.

Bicycle Therapeutics Company Profile

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.